HighTower Advisors LLC Boosts Holdings in Boston Scientific Co. (NYSE:BSX)

HighTower Advisors LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 28.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 109,978 shares of the medical equipment provider's stock after acquiring an additional 24,180 shares during the period. HighTower Advisors LLC's holdings in Boston Scientific were worth $9,241,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Triad Wealth Partners LLC purchased a new position in shares of Boston Scientific in the second quarter worth $26,000. Values First Advisors Inc. purchased a new position in shares of Boston Scientific during the third quarter worth $28,000. Andra AP fonden purchased a new position in shares of Boston Scientific during the second quarter worth $29,000. E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Boston Scientific during the third quarter worth $30,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Boston Scientific during the third quarter worth $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now directly owns 978 shares of the company's stock, valued at approximately $87,306.06. This represents a 93.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now directly owns 29,308 shares in the company, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 328,157 shares of company stock worth $27,957,676 in the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Down 1.5 %

Shares of BSX stock traded down $1.33 during trading hours on Monday, hitting $88.74. The company had a trading volume of 4,877,264 shares, compared to its average volume of 6,007,973. The company's fifty day moving average is $87.50 and its 200 day moving average is $81.44. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. Boston Scientific Co. has a fifty-two week low of $54.86 and a fifty-two week high of $91.93. The stock has a market capitalization of $130.78 billion, a PE ratio of 73.33, a price-to-earnings-growth ratio of 2.65 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period in the prior year, the business posted $0.50 EPS. The business's revenue for the quarter was up 19.3% compared to the same quarter last year. Research analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BSX. Royal Bank of Canada raised their target price on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. Evercore ISI raised their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Finally, Stifel Nicolaus raised their price target on shares of Boston Scientific from $85.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and an average price target of $93.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.